|
|
Article: Researchers review immunotherapy for allergic bronchopulmonary aspergillosis.
- Article from:
- Respiratory Therapeutics Week
- Article date:
- March 3, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 MAR 3 - (NewsRx.com & NewsRx.net) -- According to recent review from researchers in Russia and the United States, "Allergic bronchopulmonary aspergillosis (ABPA) is a severe allergic pulmonary complication caused by the saprophytic fungus Aspergillus fumigatus. The present review examines the pathogenesis of this disease describing in detail the role of innate and acquired immunity in the induction of sensitivity to A. fumigatus."
"Different approaches in developing specific immunotherapeutic treatments such as induction of anergy, regulatory cells, a switch from Th2 to Th1 type of immune response, CpG and genetic immunization and the usage of altered ...